Ceftriaxone-Induced Hemolysis in Pediatric Patients with Sickle Cell Disease

Abstract

OBJECTIVE: To provide a review on the case reports of ceftriaxone-induced hemolytic anemia in pediatric patients with sickle cell disease, present a proposed mechanism of the reaction, and provide an alternative antimicrobial regimen for these patients. DATA SOURCES: Literature retrieval was accessed through PUBMED (1985-present) using the terms pediatric, sickle cell disease, ceftriaxone, hemolytic anemia, and hemolysis. In addition, reference citations identified from these publications were reviewed. STUDY SELECTION AND DATA EXTRACTION: All articles in English identified from the data sources were evaluated. All case reports and studies were included in the review. DATA SYNTHESIS: Ceftriaxone, a third-generation cephalosporin that is frequently used for the empiric treatment of suspected infections in pediatric patients with sickle cell disease, has been linked to cases of hemolytic anemia. Ceftriaxone has many favorable attributes to promote its use: broad-spectrum anti-microbial activity, long half-life, and no requirement for dose adjustment in patients with renal dysfunction. Hemolytic anemia is a very serious condition and can be fatal. Children with sickle cell disease have a reduced number of red blood cells, and therefore, hemolytic anemia can potentially be detrimental in these children. Five case reports of ceftriaxone-induced hemolytic anemia are presented, in which the typical onset was three to seven days into therapy and all patients had received ceftriaxone courses during prior hospitalizations. There have been several proposed mechanisms of drug-induced hemolytic anemia and ceftriaxone appears to be inducing hemolysis through an immune reaction involving immunoglobulin M and complement found on the surfaces of red blood cells. The hemolysis can be managed by immediately stopping the offending agent, giving packed red blood cell transfusions, and there is possibly a role for intravenous corticosteroids, plasmapheresis, and intravenous immunoglobulin. Cefotaxime is a safe and effective alternative antibiotic in this patient population. CONCLUSIONS: Although rare, ceftriaxone appears to induce hemolytic anemia in pediatric patients with sickle cell disease. Cefotaxime provides a safe and effective alternative in this population.

Keywords

• ceftriaxone, pediatric, sickle cell disease, hemolytic anemia, hemolysis

Kaynakça

1. Garratty G. Drug-induced immune hemolytic anemia. Hematology Am Soc Hematol Educ Program 2009:73-9.
2. Petz LD, Garratty G. Acquired Immune Hemolytic Anemias Livingstone;1980:37-50. York, NY:Churchill
3. Garratty G. Immune cytopenia associated with antibiotics Transfus Med Rev 1993;7:255-267.
4. Arndt PA, Leger RM, Garratty G. Serology of antibodies cephalosporins associated with immune hemolytic anemia and/or positive direct antiglobulin tests. Transfusion 1999;39:1239-1246. third-generation
5. Quillen K, Lane C, Hu E, Pelton S, Bateman S. Prevalence of ceftriaxone-induced red blood cell antibodies in pediatric patients with sickle cell disease and human immunodeficiency virus infection. Pediatr Infect Dis J 2008;27(4):357-8.
6. Bernini JC, Mustafa MM, Sutor LJ, Buchanan GR. Fatal hemolysis induced by ceftriaxone in a child with sickle cell anemia. J Pediatr 1995;126(5 Pt 1):813-5.
7. Viner Y, Hashkes PJ, Yakubova R, Sega- Kupershmit D, Luder A. Severe hemolysis induced by ceftriaxone in a child with sickle-cell anemia. Pediatr Infect Dis J 2000;19(1):83-5.
8. Kakaiya R, Cseri J, Smith S, Simone S, Rubinas TC, Hoffstadter A. A case of acute hemolysis after ceftriaxone. 2004;128(8):905-7. Pathol Lab Med

9. Corso M, Ravindranath TM. Albuterol-induced myocardial ischemia in sickle cell anemia after hemolysis from ceftriaxone administration. Pediatr Emerg Care 2005;21(2):99-101.
10. Schuettpelz LG, Behrens D, Goldsmith MI, Druley TE. complicated by diffuse cerebral ischemia in a child with sickle cell disease. J Pediatr Hematol Oncol 2009;31:870-872. hemolysis
11. Al-Hawsawi ZM, Turkistani WA, Al-Aidaros MA, Al-Harbi DL. Ceftriaxone induced acute multi- organ failure syndrome in a Saudi boy with sickle cell disease. Saudi Med J 2010;31(7):826-828.
12. Petz LD, Garratty G. Immune Hemolytic Anemias. 2nd ed. Philadelphia: Churchill Livingstone; 2004:261-317.
13. Salama A. Drug-induced immune hemolytic anemia. Expert Opin Drug Saf 2009;8:73-79.
14. Vaglio S, Arista MC, Perrone MP, et al. Autoimmune hemolytic anemia in childhood: serologic features in 100 cases. Transfusion 2007;47(1):50-4.
15. Collins PW, Newland AC. Treatment modalities of autoimmune blood disorders. Semin Hematol 1992;29(1):64-74.
16. Arndt PA, Garratty G. Cross-Reactivity of cefotetan and ceftriaxone antibodies, associated with hemolytic anemia, with other cephalosporins and penicillin. Am J Clin Pathol 2002;118:256- 262. 26. Lexi-Comp ONLINE Web site. http://crlonline.com/crlsql/servlet/crlonline. Accessed Jan 24, 2011.